Implementing Galleri® in your practice

GRAIL has resources and support to help providers integrate Galleri into their practices. The Galleri test only requires a simple blood draw, allowing integration into existing patient touchpoints such as annual health checks or routine blood work.

Black male doctor wearing glasses, a white lab coat, and a stethoscope sitting in front of a computer in an office

Recommended use

The Galleri test is recommended for use in adults with elevated cancer risk, such as those aged 50 or older. It should be used in addition to recommended cancer screenings. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Older couple sitting together outside and looking off camera

Ordering Galleri for your patients is easy

illustrated graphic of a Black male doctor in a white lab coat reading a chart

Order the test

The Galleri test can be ordered through the Provider Portal or by completing a paper Test Requisition Form.

How to order Galleri
illustrated graphic of a white, gray haired female patient having her blood drawn

Patient specimen collection

Galleri uses a single blood draw. 

External phlebotomy providers are available nationwide.

Find a phlebotomy provider
Illustrated graphic of a tan female doctor with brown hair and blue glasses reviewing the results of a Galleri test

Receive test results

Galleri test results are available about 2 weeks after a patient’s sample has been received at GRAIL’s laboratory. 

Ordering providers receive an email notification when test results are ready. Results can be accessed via the Provider Portal.

Access test results

Payment options

The list price for the Galleri test is $949. Contact GRAIL Customer Service if you have questions about pricing.

woman in a tan sweater with medium length dark hair sitting in front of a laptop at her dining room table writing on a notepad with one hand and holding a phone in the other

FSA/HSA

Patients should work with their Flexible Spending Account (FSA) or Health Savings Account (HSA) administrator or health insurance company to determine if the Galleri test is an eligible expense.

first person POV of a laptop with payment plan on it

Payment plan

Patients may be eligible for a flexible payment plan. For additional information, contact GRAIL Customer Service at 833−694−2553.

waist up view of a smiling Asian male with brown hair wearing a white button up shirt and a gray jacket

Covered benefits

All or a portion of the Galleri test may be covered by some employers, health insurers or life insurers as a covered benefit. Patients eligible for the Galleri test as a covered benefit will be notified by the test sponsor.

Receiving your patients' Galleri test results

Galleri test results will be released to the ordering healthcare provider about two weeks after a patient’s sample has been received at GRAIL’s laboratory. Healthcare providers can access test results via the Provider Portal and/or by fax. Provider Portal users will be able to set up email notifications when new results are ready.

Woman sitting in front of a lap top wearing a white lab coat and stethoscope and writing on a notepad

Understanding Galleri test results

Sample Test Report: 

No Cancer Signal Detected

A "No Cancer Signal Detected" test result indicates that the Galleri test did not detect DNA methylation patterns that are associated with cancer. A test result of "No Cancer Signal Detected" does not rule out cancer. In the PATHFINDER clinical study, on average, fewer than 2 out of 100 people with a "No Cancer Signal Detected" result received a cancer diagnosis (Negative Predictive Value or NPV was 98.5%).1 When patients receive a “No Cancer Signal Detected” result, continue with appropriate guideline-recommended cancer screening. Consider adding Galleri to annual wellness visits in order to improve the chances of finding cancer early, when it may be more treatable.2

blue square with a white checkmark icon in the upper right corner and the text "no cancer signal detected" in the lower left corner

Sample Test Reports:

Cancer Signal Detected, 2 CSOs

Cancer Signal Detected, 1 CSO

1-2% of patients with an elevated risk for cancer taking the Galleri test receive a "Cancer Signal Detected" result.1 The Galleri test detected DNA methylation patterns that are often associated with cancer. In the PATHFINDER clinical study, on average, 4 out of 10 people with a "Cancer Signal Detected" result received a cancer diagnosis (Positive Predictive Value or PPV was 43%).1 Every “Cancer Signal Detected” result includes up to two Cancer Signal Origin predictions to guide diagnostic evaluation. With 88% accuracy* in predicting the Cancer Signal Origin, Galleri can help determine appropriate next steps to aid in rapid cancer diagnosis.1

Learn more about Cancer Signal Origin
pink square graphic with a white exclamation point icon in the upper right corner with the text "cancer signal detected" in the lower left corner

*In the PATHFINDER study for participants with a cancer diagnosis after a "Cancer Signal Detected" result.

Navigating the Galleri test result report

Test results and next steps New Test Report 1

Have more questions?

Please answer the following questions to fill in the appropriate form.

You can also contact us at (833) 694‑2553 or use the chat feature located on the bottom-right of this page for additional help.

  1. What describes you best?

  2. What are you looking for?

  3. Fill in the form

    We care about your privacy. Our Privacy Policy

    Please login to the Provider Portal if you are already an ordering provider.

    Please include information for a primary contact at your practice, should any questions come up during order processing.

    Click here to copy provider information below as the primary contact

    We care about your privacy. Our Privacy Policy

    We care about your privacy. Our Privacy Policy

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of ​“No Cancer Signal Detected” does not rule out cancer. A test result of ​“Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

  1. Schrag D, McDonnall CH, Naduld L, et al. PATHFINDER: A Prospective Study of a Multi-Cancer Early Detection Blood Test. Presentation at European Society of Medical Oncology (ESMO) Congress September 9-13, 2022; Paris, France.

  2. Sasieni P, Clarke CA, Hubbell E. Impact of MCED screening interval on reduction in late-stage cancer diagnosis and mortality. Presentation at European Society for Medical Oncology (ESMO) Virtual Congress; September 16-21, 2021.